Clinical Impact of Antibody Formation to Botulinum Toxin A in Children

Annals of Neurology

Volumn 55, Issue 5, 2004, Pages 732-735

  Herrmann, Jochen ^a   Geth, Katrin ^b   Mall, Volker ^b   Bigalke, Hans ^c   Mönting, Jürgen Schulte ^b   Linder, Michaela ^b   Kirschner, Jan ^b   Berweck, Steffen ^d   Korinthenberg, Rudolf ^b   Heinen, Florian ^d   Fietzek, Urban M ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY;

ADAPTATION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HYPERACTIVITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPERACTIVITY; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BOTULINUM TOXIN TYPE A; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE;

EID: 11144354648     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20098     Document Type: Article

References (14)

1. Tsui J, Eisen A, Stoessl A, Calne S. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986:245-246.
2. Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002;44:666-675.
3. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
4. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
5. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
6. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999;246:265-274.
7. Zuber M, Sebald M, Bathien N, et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-1718.
8. Herrmann J, Mall V, Bigalke H, et al. Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy. Neuropediatrics 2000;31:333-334.
9. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001;108:1062-1071.
10. Palisano RJ. Validity of goal attainment scaling in infants with motor delays. Phys Ther 1993;73:651-658.
11. Birklein F, Walther D, Bigalke H, et al. Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies. Ann Neurol 2002;52:68-73.
12. Göschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997;147:96-102.
13. Rosenberg JS, Middlebrook JL, Atassi MZ. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest 1997;26:491-504.
14. Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol 1991;48:1253-1256.